Korean J Gynecol Oncol Colposc.  1993 Sep;4(3):24-31.

Comparison of Serum CA125 with Serum CA130 in with Pelvic Masses

• Han JS
• Won HS
• Lee SB
• Park YB
• Nam JH
• Mok JE

Abstract

Objective
: Our object,ive was to compare the usefulness of tumor markers, serum CA125 and CA130 in differentiating malignant, fr om benign pelvic masses. Study design : Serum CA125 and CA130 levels were measured by immunoradiometric assay in total 135 sarnples which were cnllected from 91 patients with benign peluic masses, 21 patients with ovarian cancer, 3 patients with no evidence of disease after treatrnent for ovarian cancer and 20 apparently healthy . Results : In epithelial ovarian cancer, mean value of serum CA125 and CA130 were 1224.0 U/ ml and 891.0 U/ml, respectively, Serum. CA125 and CA130 levels were above 35 U/ml in 90,5% and 81.0/ af patients with maligna.nt pelvic rnasses, respectively, Serum CA130 levels showed lower false positive rate in patients with benign pelvic masses, 34.1%(>35U/ml) than that nf serurn CA125 levels 51.6%(>35U/rnl). In control group, serum CA125 and CA130 Ievels were atxwe 65 U/ml in 13.0% and 0% respectively. Values of both markers correlated each others very well. Regression equation between CA125 and CA130 is following; CA130 = 10.0+0.673 CA125 and carrelation coefficient is 0.992, Combining of CA125 and CA130, a sensitivity was 81.0% (>35U/ml) and 81.0% (>65U/ml) similar to CA125 levels alone, 90.5% (>35U/ml) and 85.7% (>65U/ml). In specificity, combining of serum CA125 aad CA130, 68.1/. (>36U/ml), 76.9 /a ( > 65U/ml) were much higher than CA125 alone, 48.4% (>36U/ml), 71.4% (>66U/ml). And diagnostic accuracy was higher in the combined use of CA125 and CA130, 69.6% (>35U/ml), 77,7% (>65U/ml) than CA125 alone, 56.3% 35U/ml), 74.1% (>65U/ml). Canclusion : Valuee of serum CA130 well correlated with thaee of CA125 and cornbined use of both markers can obtain an acceptable sensitivity and a better specificity than thous of aerum CA125 alone in ditfferentiatjng malignant from henign pelvic masses.

MeSH Terms

Humans
Immunoradiometric Assay
Ovarian Neoplasms
Sensitivity and Specificity
Biomarkers, Tumor